Bruker BioSciences Corporation to Release Third Quarter Financial Results on November 2, 2005
25 October 2005 - 6:15AM
Business Wire
Bruker BioSciences Corporation (NASDAQ:BRKR) plans to release its
third quarter 2005 financial results on Wednesday, November 2, 2005
after the market closes. Bruker BioSciences will then host an
operator-assisted earnings conference call at 5 p.m. EST. To listen
to the webcast, investors can go to www.bruker-biosciences.com and
click on the live web broadcast symbol. The webcast will be
available through the Company web site for 30 days. Investors can
also listen and participate on the telephone in the US and Canada
by calling 888-339-2688, or 617-847-3007 outside the US and Canada.
Investors should refer to the Bruker BioSciences Quarterly Earnings
Call. A telephone replay of the conference call will be available
two hours after the conference call by dialing 888-286-8010 in the
US and Canada, or 617-801-6888 outside the US and Canada, and then
entering replay pass code 39147513. ABOUT BRUKER BIOSCIENCES Bruker
BioSciences Corporation, headquartered in Billerica, Massachusetts,
is the publicly traded parent company of Bruker AXS Inc. and Bruker
Daltonics Inc. Bruker AXS is a leading developer and provider of
life science and advanced materials research tools based on X-ray
technology. Bruker Daltonics is a leading developer and provider of
innovative life science tools based on mass spectrometry. Bruker
Daltonics also offers a broad line of nuclear, biological and
chemical (NBC) detection products for defense and homeland
security. For more information, please visit
www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of the Company's products, changes in
governmental regulations, capital spending and government funding
policies, FDA and other regulatory approvals to the extent
applicable, competition, the intellectual property of others,
patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our respective annual reports
on Form 10-K for the year ended December 31, 2004, our most recent
quarterly reports on Form 10-Q, and our current reports on Form
8-K. We disclaim any intent or obligation to update these
forward-looking statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024